Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Goals of work The objective of this study was to determine the effect of infliximab, an antitumor necrosis factor alpha (TNFalpha) antibody, on fatigue in patients with advanced cancer.Materials and methods This was a pilot study undertaken in a specialist palliative care unit. Seventeen eligible outpatients were enrolled in this study. Infliximab 5 mg/kg was administered intravenously at baseline and if there was observable clinical benefit, every 4 weeks thereafter until clinical benefit was lost. The primary outcome measure assessing subjective functional improvement was the change in fatigue severity scale (FSS) score at 4 weeks following an infliximab infusion. Secondary outcome measures of subjective functional improvement that were assessed 4 weeks after each infliximab infusion included changes in Karnofsky performance status (KPS), hospital anxiety and depression scale (HADS) score, anxiety and depression subscores, and appetite visual analogue scale. Clinical laboratory assessments were C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), TNFalpha, interleukin-6, and leptin concentrations.Main results At week 4, 9 of 14 patients improved in FSS, 3 of 15 improved in KPS, 7 of 15 improved in total HADS and the majority had modest improvements in serum CRP, ESR, or leptin concentrations. Case studies of six patients with overall improvement are described in detail. Five serious adverse events occurred; two were serious infections possibly related to treatment.Conclusions A subgroup of patients in this small pilot study demonstrated uniform subjective/clinical benefit. We were not able to identify any predictors of this response; a larger, controlled study may reveal more information.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, bupropion and escitalopram have been reported to improve some aspects of verbal memory and delayed free recall.49,62”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [62]
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · cited 1×
“The following patient self-assessment questionnaires were completed: FSS, Karnofsky performance status (KPS) [11], European Organization for Research and Treatment of Cancer 30-item Quality of Life Questionnaire (EORTC QLQ 30) [1], a 100-mm visual analogue scale (VAS) appetite questionnaire where lower values represen…”
MethodAaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172 · cited 1×
“Patients who had an FSS score of 42 or greater (95% of the general population scored below 42 when this questionnaire was validated) [12, 17] were eligible for the study and received the comprehensive study information.”
MethodThe clinical evaluation of chemotherapeutic agents in cancer
Karnofsky, D. A. (1949) · Medical Entomology and Zoology · Cited by 2,933
Arky, R. A. (1994) · Cited by 2,632
TNF? and the TNF receptor superfamily: Structure-function relationship(s)
Idriss, H. T., & Naismith, J. H. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<184::aid-jemt2>3.0.co;2-h · Cited by 1,183
Evaluation of Chemotherapeutic Agents.
(1950) · Archives of Internal Medicine · doi:10.1001/archinte.1950.00230180176018 · Cited by 1,133
Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899 · cited 1×
“The safety profile of infliximab has been well documented, in both clinical studies and postmarketing experience with exposure in nearly 650,000 patients worldwide [7, 10, 14, 15].”
BackgroundTUMOR NECROSIS, CACHEXIA, SHOCK, AND INFLAMMATION: A COMMON MEDIATOR
Beutler, B., & Cerami, A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002445 · Cited by 813
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.
Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., Kuo, G. C., Beutler, B., Cotran, R. S., & Cerami, A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.3.1211 · Cited by 730 · cited 1×
“sion, and systemic symptoms related to high bulk disease [2, 19 , 20].”
BackgroundEvaluation of Chemotherapeutic Agents.
(1950) · Annals of Internal Medicine · doi:10.7326/0003-4819-32-1-168_1 · Cited by 618
Tisdale, M. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.23.1763 · Cited by 487 · cited 1×
“A unifying factor in these conditions is the production of inflammatory cytokines, one of which is tumor necrosis factor-alpha (TNFα) [3, 4, 13, 18].”
BackgroundSlifman, N. R., Gershon, S. K., Lee, J., Edwards, E. T., & Braun, M. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10758 · Cited by 383 · cited 2×
“Following publication of postmarketing surveillance data showing an increased risk of Listeria monocytogenes infection (meningitis and septicemia) [ 16 ], the protocol was amended to revise the infliximab dosing schedule and the informed consent form was updated to include this new information.”
BackgroundMethodIllness, Cytokines, and Depression
YIRMIYA, R., POLLAK, Y., MORAG, M., REICHENBERG, A., BARAK, O., AVITSUR, R., SHAVIT, Y., OVADIA, H., WEIDENFELD, J., MORAG, A., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05412.x · Cited by 284 · cited 1×
“sion, and systemic symptoms related to high bulk disease [2, 19, 20].”
BackgroundFatigue in advanced cancer: a prospective controlled cross-sectional study
Stone, P., Hardy, J., Broadley, K., Tookman, A. J., Kurowska, A., & A’Hern, R. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690236 · Cited by 277 · cited 2×
“Pain, dyspnea, insomnia, and anorexia appear to be physical symptoms most predictive of fatigue [17].”
BackgroundMethodSelf-citationThe role of cytokines in cancer-related fatigue
Kurzrock, R. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6+<1684::aid-cncr1497>3.0.co;2-z · Cited by 254
The role of cytokines in cancer cachexia
Argilés, J. M. A., & López-Soriano, F. J. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199905)19:3<223::aid-med3>3.0.co;2-n · Cited by 234 · cited 1×
“A unifying factor in these conditions is the production of inflammatory cytokines, one of which is tumor necrosis factor-alpha (TNFα) [3, 4, 13, 18].”
BackgroundReview article: safety of infliximab in clinical trials
Hanauer, S. B. (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00027.x · Cited by 172 · cited 1×
“The safety profile of infliximab has been well documented, in both clinical studies and postmarketing experience with exposure in nearly 650,000 patients worldwide [7, 10, 14, 15].”
BackgroundLong Term Safety of Infliximab
Schaible, T. F. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/698523 · Cited by 103 · cited 1×
“The safety profile of infliximab has been well documented, in both clinical studies and postmarketing experience with exposure in nearly 650,000 patients worldwide [7, 10, 14, 15].”
BackgroundCancer and beyond: the question of survivorship
Breaden, K. (1997) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.1997.00432.x · Cited by 82 · cited 1×
“Treatments are increasingly effective but often disrupt people’s lives and may be associated with long-term physical and psychological morbidity [5].”
BackgroundCouriel, D. R., Hicks, K. L., Giralt, S., & Champlin, R. E. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00011 · Cited by 65
Tumor necrosis factor-? regulates secretion of the adipocyte-derived cytokine, leptin
Finck, B. N., & Johnson, R. W. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<209::aid-jemt4>3.0.co;2-t · Cited by 52
Antunović, P., Marisavljević, D., Kraguljac, N., & Jelusic, V. (1998) · Medical Oncology · doi:10.1007/bf02787346 · Cited by 14 · cited 1×
“sion, and systemic symptoms related to high bulk disease [2, 19, 20].”
Background
Research works printed but not linked: 1
- Coleman MP, Babb P, Damiecki P, Grosclaude P et al (1999) Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS Region. Studies in Medical and Population Subjects No 61. The Stationery Office, London
Cited by
Cancer-related fatigue—mechanisms, risk factors, and treatments
Bower, J. E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.127 · Cited by 1,666
Depression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 375
“Lastly, the blockade of cytokines’ signaling has been associated with reductions in depressive symptoms and better quality of life in patients with advanced cancer [64].”
BackgroundCognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
“Evidence also demonstrates efficacy of TNF antagonists in subgroups with treatment-resistant depression.(76,77) Whether adjunctive infliximab is an efficacious approach to treating cognitive symptoms in depressive mood disorders has yet to be determined but is currently being investigated by our group in Toronto (NCT0…”
BackgroundThe biology of cancer-related fatigue: a review of the literature
Multinational Association of Supportive Care in Cancer Fatigue Study Group–Biomarker Working Group, Saligan, L. N., Olson, K., Filler, K., Larkin, D., Cramp, F., Sriram, Y., Escalante, C. P., del Giglio, A., Kober, K. M., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2763-0 · Cited by 296
“, infliximab, etanercept) resulted in the reduction in CRF [75, 76].”
BackgroundRole of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
“…studies have shown that infliximab and etanercept, another TNF-α blocker, are capable of improving symptoms of depression in patients with various inflammatory conditions (Ersozlu-Bozkirli et al , 2015; Ertenli et al , 2012; Gelfand et al , 2008; Minderhoud et al , 2007; Tookman et al , 2008).”
Metadata
- Authors
- Tookman, A. J., Jones, C. L., DeWitte, M., & Lodge, P. J.
- Affiliations
- The Royal Free Hospital (GB)
- Corresponding author
- Tookman, A. J.
- Venue
- Supportive Care in Cancer
- Published
- 2008-05-21
- Volume
- 16
- Issue
- 10
- Pages
- 1131-1140
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W1996558108
- Cited by
- 41
- References
- 22
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- cancer-related fatigue, infliximab, anti-TNF therapy, advanced cancer, palliative care, Fatigue Severity Scale, Karnofsky performance status, anxiety and depression, C-reactive protein, interleukin-6, leptin, adverse events
- MeSH terms
- Infliximab, Adult, Aged, Antibodies, Monoclonal, Fatigue, Female, Hospices, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasms, Palliative Care, Pilot Projects, Prospective Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.